Bortezomib

Search with Google Search with Bing

Information
Drug Name
Bortezomib
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma GATA2 EXPRESSION GATA2 EXPRESSION D Predictive Supports Sensitivity/Response Somatic 4 22541434 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Targeting overactive GATA2-mediated pathways with ... GATA2 GATA2 EXPRESSION GATA2 EXPRESSION Sensitivity true CIViC Evidence detail
- ATF4 ATF4 UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Obatoclax is a Bcl-2 family (including Mcl-1) inhi... MCL1 MCL1 UNDEREXPRESSION Sensitivity true MMMP detail
In this model bortezomib seems to act by increasin... MCL1 MCL1 UNDEREXPRESSION Sensitivity true MMMP detail
Gossypol inhibits Bcl-2, Bcl-xL and Mcl-1, but siR... MCL1 MCL1 UNDEREXPRESSION Sensitivity true MMMP detail
This drug combination works also in Bcl-2 or Mcl-1... IFNAR1 IFNAR1 OVEREXPRESSION Sensitivity true MMMP detail
In this model bortezomib seems to act by increasin... MCL1 MCL1 UNDEREXPRESSION Sensitivity true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT03942224 Active, not recruiting Phase 2 Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma July 3, 2019 July 31, 2025
NCT03829020 Active, not recruiting Phase 1 Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma April 17, 2019 August 2024
NCT04751877 Active, not recruiting Phase 3 Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). July 17, 2021 August 17, 2027
NCT02375555 Active, not recruiting Phase 2 Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM May 7, 2015 July 30, 2024
NCT03652064 Active, not recruiting Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy November 6, 2018 October 31, 2028
NCT05083169 Active, not recruiting Phase 3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma October 14, 2021 December 8, 2028
NCT02343042 Active, not recruiting Phase 1/Phase 2 Selinexor and Backbone Treatments of Multiple Myeloma Patients October 2015 April 2027
NCT03117751 Active, not recruiting Phase 2/Phase 3 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma March 29, 2017 March 31, 2028
NCT03651128 Active, not recruiting Phase 3 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) April 16, 2019 April 8, 2027
NCT00092222 Active, not recruiting Phase 2 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity October 28, 2004 October 1, 2025
NCT03110562 Active, not recruiting Phase 3 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma May 24, 2017 September 1, 2023
NCT03617731 Active, not recruiting Phase 3 Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) October 18, 2018 December 2025
NCT05556616 Active, not recruiting Phase 1 A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma October 27, 2022 June 4, 2024
NCT05564052 Active, not recruiting Phase 2 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma December 6, 2022 September 30, 2024
NCT00378105 Active, not recruiting Phase 1/Phase 2 Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma September 2006 September 2024
NCT04570631 Active, not recruiting Phase 1 Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma November 5, 2020 July 30, 2024
NCT03004287 Active, not recruiting Phase 2 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy July 1, 2017 October 2025
NCT02112916 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma October 4, 2014 September 22, 2024
NCT03828292 Active, not recruiting Phase 1 An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments March 14, 2019 December 31, 2024
NCT06215638 Active, not recruiting N/A An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis March 1, 2023 December 30, 2024
NCT04246047 Active, not recruiting Phase 3 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma May 7, 2020 June 19, 2026
NCT02783625 Active, not recruiting Phase 1 Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas May 2016 May 2024
NCT03989414 Active, not recruiting Phase 1/Phase 2 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) September 30, 2019 November 30, 2026
NCT03319667 Active, not recruiting Phase 3 Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant December 7, 2017 June 30, 2027
NCT04166565 Active, not recruiting Phase 2 Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease October 31, 2019 March 2027
NCT00479128 Active, not recruiting Phase 1 Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors September 28, 2006 September 30, 2024
NCT00644228 Active, not recruiting Phase 3 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma April 1, 2008 March 7, 2025
NCT04722146 Active, not recruiting Phase 1 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma March 12, 2021 February 24, 2025
NCT00492050 Active, not recruiting Phase 2 Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia August 2, 2006 June 28, 2024
NCT01863550 Active, not recruiting Phase 3 Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma December 6, 2013 February 5, 2034
NCT02773030 Active, not recruiting Phase 1/Phase 2 A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma October 14, 2016 February 6, 2028
NCT03763162 Active, not recruiting Phase 2 Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma January 17, 2019 December 31, 2024
NCT03742297 Active, not recruiting Phase 3 Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years October 22, 2018 January 2031
NCT02719613 Active, not recruiting Phase 2 Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab July 15, 2016 June 28, 2024
NCT01861314 Active, not recruiting Phase 1 Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia July 3, 2013 March 7, 2025
NCT02718833 Active, not recruiting Phase 2 A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma June 21, 2016 June 2025
NCT04140162 Active, not recruiting Phase 2 Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy October 5, 2020 August 2026
NCT03314181 Active, not recruiting Phase 2 A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma April 2, 2018 August 21, 2025
NCT03201965 Active, not recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis October 5, 2017 August 16, 2024
NCT01695941 Active, not recruiting Phase 1 Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma August 31, 2012 March 5, 2025
NCT01668719 Active, not recruiting Phase 1/Phase 2 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma November 2012 June 2024
NCT01415752 Active, not recruiting Phase 2 Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma August 9, 2012 September 2031
NCT03984097 Active, not recruiting Phase 1 A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) July 29, 2019 February 23, 2025
NCT02555839 Active, not recruiting Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice February 20, 2015 December 31, 2023
NCT01371981 Active, not recruiting Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia June 20, 2011 September 30, 2027
NCT04133636 Active, not recruiting Phase 2 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma November 7, 2019 November 13, 2028
NCT02553460 Active, not recruiting Phase 1/Phase 2 Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I January 29, 2016 October 2031
NCT03188172 Active, not recruiting Phase 2 MUK Nine b: OPTIMUM Treatment Protocol September 28, 2017 May 31, 2026
NCT01286272 Active, not recruiting Phase 2 Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma April 8, 2011 March 7, 2025
NCT04181827 Active, not recruiting Phase 3 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma June 12, 2020 June 30, 2027
NCT01208662 Active, not recruiting Phase 3 Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 October 2010 September 2025
NCT02441686 Active, not recruiting Phase 2 Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma December 2015 June 2025
NCT01163357 Active, not recruiting Phase 1 Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma January 28, 2011 December 31, 2024
NCT03695744 Active, not recruiting Phase 2 Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma October 2, 2019 April 2024
NCT00107341 Completed Phase 2 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction August 2005 May 2008
NCT00108069 Completed Phase 2 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors April 2005 March 2013
NCT00111319 Completed Phase 3 VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma December 2004
NCT00111813 Completed Phase 1 Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) September 2005 May 2011
NCT00114738 Completed Phase 2 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma June 15, 2005 August 11, 2022
NCT00118144 Completed Phase 2 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer June 2005 December 2010
NCT00118183 Completed Phase 2 Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer July 2005
NCT00129207 Completed Phase 1 Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
NCT00148317 Completed Phase 2 Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma June 2005 November 2012
NCT00153920 Completed Phase 2 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma December 2003 September 2008
NCT00153933 Completed Phase 1 Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma August 2004 July 2014
NCT00182637 Completed Phase 2 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma July 2004 September 2010
NCT00193232 Completed Phase 2 Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer May 2004 February 2007
NCT00193557 Completed Phase 2 Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma May 2004 January 2009
NCT00216697 Completed Phase 2 An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy March 2005 October 2006
NCT00217503 Completed Phase 2 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma July 2005 June 2007
NCT00227513 Completed Phase 1 Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors July 2005
NCT00250926 Completed Phase 2 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia October 2005 February 2009
NCT00257114 Completed Phase 4 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00258245 Completed Phase 1 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia May 2005 April 2008
NCT00262860 Completed Phase 2 Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma April 2005
NCT00262873 Completed Phase 2 Bortezomib in Treating Patients With Myelodysplastic Syndromes May 2005 October 2010
NCT00276614 Completed Phase 2 Bortezomib in Treating Patients With Metastatic Kidney Cancer April 2006 July 2009
NCT00280176 Completed Phase 1 Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer April 2003 September 2010
NCT00287872 Completed Phase 2 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma September 2004 November 2010
NCT00288028 Completed Phase 1 Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant July 2005 June 2012
NCT00288041 Completed Phase 2 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma October 2005
NCT00290680 Completed Phase 1 Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors March 2005 January 2009
NCT00291538 Completed Phase 1 Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma February 2006 October 2008
NCT00295932 Completed Phase 1/Phase 2 Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma December 13, 2005 March 11, 2018
NCT00305734 Completed Phase 2 Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer August 2006
NCT00307086 Completed Phase 2 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants June 2005 March 2012
NCT00310024 Completed Phase 1 Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma November 2005
NCT00315757 Completed Phase 2 Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma May 2006 October 2010
NCT00316940 Completed Phase 1 Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma December 2005 February 2011
NCT00317811 Completed Phase 2 Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma November 2005
NCT00334438 Completed Phase 1 Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma July 2006 October 2011
NCT00335348 Completed Phase 2 Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse June 2006 July 2012
NCT00348985 Completed Phase 1 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas March 2006
NCT00358020 Completed Phase 2 Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients November 2004 December 2008
NCT00362882 Completed Phase 2 Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer July 2006 July 2010
NCT00369707 Completed Phase 2 Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL August 9, 2006 October 10, 2014
NCT00376961 Completed Phase 2 S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma August 2006 September 2017
NCT00377052 Completed Phase 2 Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma January 16, 2007 June 21, 2011
NCT00378209 Completed Phase 2 Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma August 2006 October 2016
NCT00379574 Completed Phase 1/Phase 2 Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL September 2006 January 2011
NCT00381940 Completed Phase 2 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy January 2007 December 31, 2016
NCT00383474 Completed Phase 1 Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase August 2006 June 2012
NCT00388089 Completed Phase 1 Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors December 2004 June 2008
NCT00389805 Completed Phase 1/Phase 2 Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors March 2005 June 2007
NCT00401011 Completed Phase 1/Phase 2 Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients August 2006 July 2011
NCT00401843 Completed Phase 2 A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma November 28, 2006 September 24, 2019
NCT00407303 Completed Phase 1/Phase 2 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) October 2006 November 2009
NCT00408928 Completed Phase 2 Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease November 2005 September 2009
NCT00416208 Completed Phase 3 Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma October 2006 May 2013
NCT00416273 Completed Phase 3 A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma December 2006 May 2013
NCT00417911 Completed Phase 3 Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients December 2005 May 2010
NCT00422799 Completed Phase 2 Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) August 30, 2006 October 9, 2015
NCT00425750 Completed Phase 2 Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer August 2005 June 2009
NCT00426855 Completed Phase 1/Phase 2 Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) January 2007 June 2009
NCT00428142 Completed Phase 2 Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma May 1, 2007 January 6, 2012
NCT00428545 Completed Phase 1 Bevacizumab and Bortezomib in Patients With Advanced Malignancy January 2007 November 2012
NCT00431769 Completed Phase 2 An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma June 2006 January 2010
NCT00433537 Completed Phase 2 Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma May 2007 June 2013
NCT00436059 Completed Phase 2 The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) February 2007 July 2009
NCT00439361 Completed Phase 1 Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma February 2007 June 2012
NCT00439556 Completed Phase 2 Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant February 13, 2007 June 7, 2018
NCT00440479 Completed ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. September 2006 January 2011
NCT00440726 Completed Phase 1/Phase 2 Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) August 4, 2006 February 26, 2011
NCT00440765 Completed VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands November 2004 January 2012
NCT00458705 Completed Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma November 2006 April 2011
NCT00458822 Completed Phase 2 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis February 2007 March 2015
NCT00004002 Completed Phase 1 PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma July 1999
NCT00473590 Completed Phase 2 A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) June 2007 November 2009
NCT00477412 Completed Phase 1/Phase 2 Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma April 3, 2007 October 28, 2020
NCT00478075 Completed Phase 1/Phase 2 Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma September 2005 June 2009
NCT00483262 Completed Phase 1/Phase 2 Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma May 2007 February 2012
NCT00504634 Completed Phase 2 Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma January 2004 May 2010
NCT00507416 Completed Phase 3 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone June 2007 March 2013
NCT00511069 Completed Phase 2 Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia July 2006 February 2008
NCT00513877 Completed Phase 2 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma May 2006
NCT00513955 Completed Phase 2 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma June 2006 October 2014
NCT00514371 Completed Phase 2/Phase 3 A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma August 2007 February 2009
NCT00520767 Completed Phase 2 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease September 2007 June 6, 2019
NCT00523848 Completed Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma June 2006 October 2012
NCT00536575 Completed Phase 1/Phase 2 Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients November 2007 August 2010
NCT00541359 Completed Phase 1 Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors January 2004 June 2011
NCT00544284 Completed Phase 1 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment January 2005 January 2012
NCT00546780 Completed Phase 3 A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse February 2008 March 2010
NCT00547534 Completed Phase 2 Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma October 2007 October 2009
NCT00553644 Completed Phase 2 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma November 15, 2007 January 21, 2014
NCT00555906 Completed Phase 2 An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. January 2008 March 2013
NCT00564200 Completed Phase 2 MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning November 2007 October 2014
NCT00568880 Completed Phase 1 Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma September 8, 2010 June 22, 2011
NCT00570180 Completed Phase 2 Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma August 25, 2008 September 15, 2015
NCT00571493 Completed Phase 1/Phase 2 VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma April 14, 2006 November 1, 2014
NCT00580242 Completed Phase 1 A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia November 2007 March 2012
NCT00581776 Completed Phase 2 Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma May 2005 May 2015
NCT00598169 Completed Phase 1 Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma November 2007 November 2014
NCT00602511 Completed Phase 3 Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma October 2007 December 2010
NCT00608907 Completed Phase 1 An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) September 2007 April 2010
NCT00609167 Completed Phase 2 Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma December 2006 November 2010
NCT00611325 Completed Phase 2 Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma May 2008 October 2013
NCT00620295 Completed Phase 1 Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors March 2007 October 2009
NCT00622674 Completed Phase 1 Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors November 2005 February 2010
NCT00629226 Completed Phase 1 Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer October 2007
NCT00633594 Completed Phase 1/Phase 2 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma June 2008 November 2016
NCT00634179 Completed Phase 1/Phase 2 A Phase I/II Trial of VR-CHOP in Lymphoma Patients February 2008 November 2015
NCT00641706 Completed Phase 2 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme July 2008 November 2010
NCT00642395 Completed Phase 2 Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) July 2007 July 2011
NCT00651781 Completed Phase 1/Phase 2 Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia April 2008 February 2013
NCT00652041 Completed Phase 4 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma January 2007 June 2010
NCT00664898 Completed Phase 1 A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma May 2008 April 8, 2010
NCT00666588 Completed Phase 2 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia April 2008 December 2012
NCT00667641 Completed Phase 1 Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors March 2007 February 2009
NCT00670423 Completed Phase 1 A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation May 16, 2008 October 16, 2013
NCT00703300 Completed Phase 1 Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia June 2008 October 2014
NCT00703664 Completed Phase 2 Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma July 9, 2008 December 1, 2017
NCT00708292 Completed Phase 1/Phase 2 A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. July 2008 January 2011
NCT00711828 Completed Phase 2 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma August 2008 April 6, 2018
NCT00720785 Completed Phase 1 Natural Killer Cells and Bortezomib to Treat Cancer August 1, 2008 April 6, 2021
NCT00722722 Completed Phase 2 The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates June 2008 April 2014
NCT00724568 Completed Phase 1/Phase 2 Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma May 2008 September 3, 2014
NCT00734149 Completed Phase 2 Bortezomib With Melphalan and Prednisone for Multiple Myeloma July 2004 February 2008
NCT00740415 Completed Phase 2 Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma June 2007 August 2015
NCT00742625 Completed Phase 1/Phase 2 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia September 2008 December 2012
NCT00752518 Completed Phase 1/Phase 2 A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients May 2004 January 2006
NCT00771875 Completed Phase 2 Randomized Trial for Mixed Acute Rejection September 2008 March 2013
NCT00458913 Completed Phase 2 Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma February 2007 March 2012
NCT00005064 Completed Phase 1 PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome February 2000
NCT00006098 Completed Phase 1 PS-341 in Treating Patients With Hematologic Cancer April 2000 October 2001
NCT00006184 Completed Phase 2 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma February 8, 2001 January 12, 2008
NCT00006362 Completed Phase 1 PS-341 in Treating Patients With Advanced Cancer November 1999 August 2003
NCT00007878 Completed Phase 1 Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery September 2000
NCT00011778 Completed Phase 1 PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck February 22, 2001 February 8, 2013
NCT00017199 Completed Phase 2 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors April 2001 May 2007
NCT00017329 Completed Phase 2 PS-341 in Treating Patients With Metastatic Kidney Cancer April 2001
NCT00021216 Completed Phase 1 Bortezomib in Treating Children With Advanced Solid Tumors November 2001 December 2005
NCT00023712 Completed Phase 2 Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer November 5, 2001 January 2010
NCT00023764 Completed Phase 2 Bortezomib in Treating Patients With Lymphoproliferative Disorders June 2001 March 2009
NCT00023855 Completed Phase 1 PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors June 2001
NCT00024011 Completed Phase 2 PS-341 in Treating Patients With Metastatic Malignant Melanoma July 2001
NCT00025584 Completed Phase 2 PS-341 in Treating Women With Metastatic Breast Cancer August 2001
NCT00027716 Completed Phase 2 Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma October 2001 May 2004
NCT00027898 Completed Phase 1 Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors January 2002
NCT00028587 Completed Phase 1 PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors December 2001
NCT00028639 Completed Phase 2 PS-341 in Treating Women With Metastatic Breast Cancer August 2001 November 2003
NCT00028912 Completed Phase 1 Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer November 2001
NCT00030368 Completed Phase 1 Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors November 2001
NCT00030875 Completed Phase 2 Bortezomib in Treating Patients With Mantle Cell Lymphoma November 19, 2002 December 21, 2009
NCT00045695 Completed Phase 2 Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia August 2002 December 2009
NCT00048230 Completed Phase 3 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma June 2002 December 2004
NCT00052338 Completed Phase 1 Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer September 2002
NCT00052507 Completed Phase 2 Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer January 2003
NCT00052689 Completed Phase 2 Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer December 2002
NCT00054483 Completed Phase 1 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction January 2003
NCT00061932 Completed Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach April 2003 November 2013
NCT00063726 Completed Phase 3 A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 April 2002 July 2005
NCT00064012 Completed Phase 2 Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer May 2003 July 2004
NCT00066352 Completed Phase 2 Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter September 2003
NCT00066508 Completed Phase 2 Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy May 2003
NCT00068289 Completed Phase 2 Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy September 2003 July 2007
NCT00068315 Completed Phase 1 Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia July 2003
NCT00068484 Completed Phase 1 A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies July 2003
NCT00072150 Completed Phase 2 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma October 2003
NCT00074009 Completed Phase 2 Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma October 2003
NCT00075751 Completed Phase 2 Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer January 2004
NCT00075881 Completed Phase 2 Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma January 2004 October 2012
NCT00077428 Completed Phase 2 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck June 2004
NCT00077441 Completed Phase 2 Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) April 2005
NCT00077467 Completed Phase 1 Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia January 2004
NCT00080405 Completed Phase 1 Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma March 2004
NCT00082784 Completed Phase 1 Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms March 2004 September 2014
NCT00083226 Completed Phase 2 Doxorubicin and Bortezomib in Treating Patients With Liver Cancer March 2004 August 2012
NCT00084747 Completed Phase 1/Phase 2 Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma June 2004 January 2013
NCT00088855 Completed Phase 2 Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma June 15, 2004 January 8, 2008
NCT00091117 Completed Phase 1 Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction July 2004
NCT00093028 Completed Phase 3 Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II January 2004 January 2006
NCT00093756 Completed Phase 1/Phase 2 Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer September 2004 May 2013
NCT00098982 Completed Phase 1 Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer September 2004
NCT00103259 Completed Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck July 2005 November 2011
NCT00104871 Completed Phase 2 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy December 2004 April 2014
NCT00773747 Completed Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) December 1, 2008 June 30, 2015
NCT00773838 Completed Phase 2 Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) December 1, 2008 April 9, 2012
NCT00777738 Completed Phase 2 Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia October 2008 August 2012
NCT00789256 Completed N/A Low Dose Melphalan and Bortezomib for AML and High-Risk MDS September 2004 December 2008
NCT00790647 Completed Phase 2 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis June 2008 November 2014
NCT00791011 Completed Phase 1 Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat February 2008 August 2011
NCT00792142 Completed Phase 2 Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma January 16, 2008 April 21, 2014
NCT00793572 Completed Phase 2 Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma October 2008 October 2016
NCT00798720 Completed Phase 2 Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer December 2008 October 2012
NCT00813150 Completed Phase 3 Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma January 2009 January 2013
NCT00814541 Completed Phase 2 PAD. ICORG 05-01, V11 December 2005 December 2012
NCT00815919 Completed Phase 2 Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease December 2008 January 2013
NCT00833560 Completed Phase 2 A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy March 2006 June 2009
NCT00839956 Completed Phase 2 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant February 2009 March 31, 2017
NCT00858234 Completed Phase 1 Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) February 13, 2009 April 19, 2012
NCT00863369 Completed Phase 1/Phase 2 Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma June 29, 2005 June 20, 2023
NCT00873093 Completed Phase 2 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma March 2009 September 2014
NCT00884546 Completed Phase 1 Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma July 2009 March 2012
NCT00895687 Completed Phase 1 Study of Erlotinib in Combination With Bortezomib April 2009
NCT00903968 Completed Phase 1/Phase 2 Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma June 1, 2009 October 2016
NCT00908232 Completed Phase 2 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD May 2008 August 2011
NCT00908583 Completed Phase 4 Desensitization in Kidney Transplantation May 2009 November 2012
NCT00920855 Completed Phase 1/Phase 2 Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma June 2009 December 2011
NCT00931918 Completed Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients October 2009 August 2015
NCT00937495 Completed Phase 2 Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma June 2009 June 2011
NCT00948922 Completed Phase 2 Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma June 18, 2009 May 14, 2019
NCT00958256 Completed Phase 2 Study of Bortezomib in Combination With Cyclophosphamide and Rituximab August 2009 March 2014
NCT00963274 Completed Phase 1 Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma April 26, 2010 April 13, 2018
NCT00967369 Completed Phase 2 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. August 24, 2009 May 2, 2018
NCT00972959 Completed Phase 2 Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy July 2009 May 2013
NCT00980395 Completed Phase 2 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma July 7, 2009 August 14, 2018
NCT00990652 Completed Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide May 2009 October 2012
NCT00992446 Completed Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma September 2, 2010 October 29, 2019
NCT00994500 Completed Phase 1 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma August 2009
NCT01000285 Completed Phase 1/Phase 2 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma September 2010 April 2016
NCT01005628 Completed Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) June 2006 March 2012
NCT01009840 Completed Phase 2 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients May 2010 March 2012
NCT01016730 Completed Phase 1 Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma January 22, 2010 January 7, 2015
NCT01021592 Completed Quality of Life in Multiple Myeloma Patients Treated With Bortezomib March 2007 July 2008
NCT01023308 Completed Phase 3 Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma December 21, 2009 July 30, 2015
NCT01026701 Completed Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. March 2008 November 2009
NCT01029730 Completed Phase 2 Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma March 2010 July 2016
NCT01030302 Completed A Retreatment Study With Bortezomib for Multiple Myeloma November 2008 September 2010
NCT01034553 Completed Phase 1/Phase 2 Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma February 2010 November 2014
NCT01038388 Completed Phase 1 A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma January 15, 2010 August 5, 2021
NCT01056276 Completed Phase 2 Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy May 2010 February 2017
NCT01058239 Completed Phase 2 Bortezomib Plus Rituximab for EBV+ PTLD November 2011 November 2017
NCT01063907 Completed Phase 1/Phase 2 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma March 2010 November 2013
NCT01072773 Completed Phase 2 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis March 2010 June 2012
NCT01074411 Completed Phase 1 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer April 5, 2010 January 27, 2018
NCT01075425 Completed Phase 1 Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome May 2010 February 2015
NCT01078454 Completed Phase 3 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis November 2010 November 27, 2012
NCT01078961 Completed Phase 1 An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma September 2010 June 2016
NCT01083316 Completed Phase 2 Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis September 2009 September 4, 2020
NCT01083602 Completed Phase 2 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma June 2010 February 2014
NCT01088048 Completed Phase 1 Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia March 25, 2010 April 28, 2015
NCT01090921 Completed Phase 2 Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma May 2007 March 2015
NCT01127009 Completed Phase 1 Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia July 2010 May 2014
NCT01129180 Completed Phase 1 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma May 2010 December 2012
NCT01142401 Completed Phase 2 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer May 26, 2010 January 8, 2021
NCT01164709 Completed Phase 1 Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer July 2010 November 2013
NCT01174888 Completed Phase 1 Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia August 2010 May 2016
NCT01183949 Completed Phase 1/Phase 2 Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma November 2010 March 2015
NCT01212952 Completed Phase 1/Phase 2 Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma September 2011 March 22, 2018
NCT01216683 Completed Phase 2 Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma February 9, 2011 December 2, 2019
NCT01241708 Completed Phase 3 Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma April 8, 2010 July 15, 2023
NCT01267812 Completed Phase 2 Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation October 3, 2011 November 2, 2020
NCT01273844 Completed N/A Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) March 1, 2011 May 12, 2016
NCT01286077 Completed Phase 2 Velcade Consolidation Bone Study September 2009 April 2014
NCT01313897 Completed Phase 2 UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma January 2011 October 2016
NCT01323920 Completed Phase 2 Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors May 2011 November 2013
NCT01324596 Completed Phase 3 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib April 2011 June 2015
NCT01337752 Completed Phase 2 Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency January 2012 May 2013
NCT01359657 Completed Phase 1 Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma September 2011 March 2016
NCT01381692 Completed Phase 1/Phase 2 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma July 20, 2011 September 1, 2021
NCT01394354 Completed Phase 1/Phase 2 Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) August 2011 December 2015
NCT01420926 Completed Phase 2 Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia November 16, 2011 April 1, 2021
NCT01428492 Completed Phase 1 Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma December 2011 October 2015
NCT01440582 Completed Phase 1 Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients February 18, 2013 February 28, 2019
NCT01462773 Completed Phase 1 Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma January 2006 April 2013
NCT01478048 Completed Phase 2 Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma November 30, 2011 April 21, 2017
NCT01481194 Completed Phase 2 ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma November 2011 August 28, 2018
NCT01485835 Completed Phase 1 A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma January 2012 September 2015
NCT01497093 Completed Phase 1 Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma February 15, 2012 July 23, 2019
NCT01504776 Completed Phase 1 Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) April 2011 September 2014
NCT01517724 Completed Phase 2 Bortezomib Consolidation Trial December 2009 January 24, 2019
NCT01531998 Completed Phase 1/Phase 2 Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) May 2012 May 2014
NCT01539083 Completed Phase 3 Velcade (Bortezomib) Consolidation After Transplant January 13, 2012 January 9, 2018
NCT01568866 Completed Phase 3 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients June 20, 2012 February 5, 2018
NCT01592981 Completed Phase 2 Randomised Trial in Waldenstrom's Macroglobulinaemia January 2013 August 2, 2020
NCT01594242 Completed Early Phase 1 Autophagy Induction After Bortezomib for Myeloma July 10, 2012 March 2, 2015
NCT01602224 Completed Phase 2 A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) July 2012 July 2014
NCT01605032 Completed Phase 2 Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma February 2012 March 2018
NCT01633645 Completed Phase 2 Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer June 2009 April 2013
NCT01672229 Completed Phase 1 Bortezomib in Patients With Chronic Graft Versus Host Disease July 2012 April 9, 2018
NCT01696474 Completed Phase 2 Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease December 2012 March 27, 2017
NCT01706666 Completed Phase 2 Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant December 7, 2012 May 17, 2016
NCT01711528 Completed Phase 1 Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma December 19, 2012 November 22, 2016
NCT01734928 Completed Phase 3 Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma January 7, 2013 May 13, 2022
NCT01736943 Completed Phase 2 Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia December 19, 2012 May 20, 2019
NCT01754389 Completed Phase 2 Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant January 2013 November 2016
NCT01769209 Completed Phase 2 Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia March 2013 July 4, 2017
NCT01782963 Completed Phase 2 Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) March 2013 December 2017
NCT01794507 Completed Phase 1 A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy November 19, 2012 July 16, 2019
NCT01801436 Completed Phase 3 A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma December 2006 April 2008
NCT01818752 Completed Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma July 8, 2013 November 4, 2016
NCT01833143 Completed Phase 2 Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D April 11, 2013 August 28, 2019
NCT01848132 Completed Phase 2 Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. October 3, 2013 August 2018
NCT01849783 Completed Phase 2 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma April 4, 2013 September 30, 2020
NCT01873157 Completed Phase 2 Bortezomib in Late Antibody-mediated Kidney Transplant Rejection December 2013 February 28, 2017
NCT01891968 Completed Phase 2 Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation August 7, 2013 January 18, 2017
NCT01913730 Completed Phase 2 Maintenance Therapy With Subcutaneous Bortezomib November 2013 September 7, 2023
NCT01919086 Completed Phase 2 Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma August 6, 2013 May 16, 2024
NCT01929980 Completed Phase 2 Bortezomib to Treat Significant Complication of HSCT July 2012 May 2014
NCT01936090 Completed Phase 1 Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma August 2013 February 16, 2018
NCT01965353 Completed Phase 1 A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma October 2013 September 2021
NCT01998503 Completed Phase 3 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis December 2007 August 2013
NCT02026505 Completed Evaluation of Cardiotoxic Effects of Bortezomib March 1, 2014 March 1, 2019
NCT02037256 Completed N/A Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma July 2011 January 21, 2015
NCT02057380 Completed Phase 2 A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial April 16, 2014 December 21, 2016
NCT02100657 Completed Phase 1 Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma June 2014 June 2018
NCT02139397 Completed Phase 1/Phase 2 Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma June 6, 2014 January 19, 2024
NCT02188537 Completed Phase 2 Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma December 2, 2014 April 17, 2018
NCT02201576 Completed Phase 2 Bortezomib in Rejection of Kidney Transplants February 11, 2015 July 16, 2020
NCT02208037 Completed Phase 2 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) August 2014 October 2017
NCT02220049 Completed Phase 1 Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors December 2010 November 2013
NCT02220608 Completed Phase 1 Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma February 20, 2015 November 30, 2016
NCT02224729 Completed Phase 2 Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma August 25, 2014 November 17, 2018
NCT02268890 Completed Phase 4 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma December 2014 July 2015
NCT02290431 Completed Phase 2 Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma December 16, 2014 December 25, 2018
NCT02352558 Completed Phase 1 A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies May 2015 May 16, 2019
NCT02370693 Completed Phase 2 Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis March 2016 January 1, 2020
NCT02424851 Completed Phase 2 Optimising Renal Outcome in Myeloma Renal Failure November 2014 April 20, 2020
NCT02440464 Completed Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) August 2015 October 1, 2020
NCT02467010 Completed Phase 2 Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance September 2008 July 2013
NCT02474563 Completed Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma May 2011 May 2014
NCT02481934 Completed Phase 1 Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma March 2013 October 2016
NCT02495922 Completed Phase 3 A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma June 2015 June 24, 2021
NCT02497378 Completed Phase 1 A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma July 10, 2015 March 6, 2018
NCT02500251 Completed Phase 1/Phase 2 Belimumab Impacting Transplant Eligibility June 2015 August 2018
NCT02513186 Completed Phase 1 Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation September 30, 2015 January 22, 2024
NCT02514382 Completed Phase 1 Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma August 21, 2015 April 19, 2022
NCT02613598 Completed Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma May 12, 2016 June 7, 2021
NCT02703779 Completed Phase 2 Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) March 2016 April 8, 2020
NCT02755597 Completed Phase 3 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy July 11, 2016 August 15, 2022
NCT02811978 Completed Phase 3 Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma September 27, 2016 November 10, 2018
NCT02874742 Completed Phase 2 Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma August 29, 2016 April 8, 2022
NCT02893111 Completed Phase 2 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder December 2015 January 31, 2017
NCT02902965 Completed Phase 2 Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma September 20, 2016 October 26, 2018
NCT02951819 Completed Phase 2 A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma November 9, 2016 August 17, 2020
NCT02977494 Completed Phase 2 Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment June 2016 June 2021
NCT03344328 Completed Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. January 15, 2019 January 31, 2020
NCT03401372 Completed N/A BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients April 21, 2018 December 31, 2020
NCT03412565 Completed Phase 2 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens April 26, 2018 April 18, 2024
NCT03416374 Completed Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy February 18, 2018 May 28, 2021
NCT03544281 Completed Phase 1/Phase 2 To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) September 20, 2018 February 29, 2024
NCT03945591 Completed Phase 2 High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) June 20, 2019 January 4, 2024
NCT04173585 Completed Phase 2 TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib October 22, 2019 March 24, 2023
NCT04892446 Completed Phase 2 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma November 9, 2021 April 25, 2024
NCT05163405 Completed Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma. December 1, 2019 June 1, 2022
NCT06012383 Completed Alvocade® (Bortezomib) Safety and Effectiveness Study July 2016 December 2022
NCT00063791 No longer available A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
NCT00799539 No longer available A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
NCT02666209 No longer available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT06015750 Not yet recruiting Phase 4 Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia April 30, 2024 April 28, 2028
NCT06348147 Not yet recruiting Phase 2 Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation August 2024 August 2028
NCT05558319 Not yet recruiting Phase 3 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide October 2022 April 2029
NCT05147493 Not yet recruiting Phase 2 A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment April 2022 February 2025
NCT06413498 Not yet recruiting Phase 3 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma October 2024 July 2031
NCT06390319 Not yet recruiting Phase 2 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) June 2024 December 2033
NCT06353022 Not yet recruiting Phase 2 Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma April 20, 2024 June 20, 2030
NCT06022939 Not yet recruiting Phase 3 Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis July 1, 2024 October 29, 2030
NCT05272826 Not yet recruiting Phase 2 Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients October 2024 March 2031
NCT06464991 Recruiting Phase 3 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) March 27, 2024 December 2030
NCT05137054 Recruiting Phase 1 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments August 17, 2022 January 23, 2033
NCT05218603 Recruiting Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT November 30, 2021 November 6, 2025
NCT05250973 Recruiting Phase 2 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis March 1, 2022 December 31, 2027
NCT05257083 Recruiting Phase 3 A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma October 10, 2023 August 2040
NCT05289167 Recruiting Phase 1/Phase 2 High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study March 13, 2022 December 2026
NCT05392946 Recruiting Phase 1/Phase 2 Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study August 11, 2022 May 2028
NCT05422027 Recruiting Phase 1/Phase 2 Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma July 25, 2022 December 31, 2025
NCT05432414 Recruiting Phase 2 PVd Versus Vd in NDMM Patients With RI December 8, 2022 July 31, 2024
NCT05514990 Recruiting Phase 1/Phase 2 Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial October 7, 2022 October 7, 2026
NCT05519085 Recruiting Phase 3 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) September 20, 2022 November 30, 2033
NCT05561387 Recruiting Phase 3 Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment October 12, 2023 April 15, 2030
NCT05572515 Recruiting Phase 3 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma March 29, 2023 August 31, 2031
NCT05599880 Recruiting Phase 2 The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia July 7, 2023 December 31, 2027
NCT05665140 Recruiting Phase 2/Phase 3 Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients February 3, 2023 October 2028
NCT05695508 Recruiting Phase 2 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 December 1, 2022 October 15, 2027
NCT05736419 Recruiting Phase 2 A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) February 9, 2023 February 9, 2026
NCT05804032 Recruiting Phase 3 Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma April 14, 2023 July 24, 2026
NCT05805891 Recruiting N/A Bortezomib for the Treatment of Refractory Rheumatoid Arthritis December 2023 December 2025
NCT05848687 Recruiting Phase 1/Phase 2 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II November 3, 2023 December 2033
NCT05849610 Recruiting Phase 2 Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma November 2023 July 2029
NCT05900882 Recruiting Phase 2 SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease July 15, 2022 June 30, 2025
NCT05123131 Recruiting Phase 2 Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma April 1, 2022 December 15, 2027
NCT06029998 Recruiting Phase 2 Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion March 11, 2024 December 2028
NCT06034561 Recruiting Phase 2 Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia April 1, 2024 August 2029
NCT06083922 Recruiting Phase 2 A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) October 16, 2023 October 2026
NCT06140966 Recruiting Phase 2 Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma October 20, 2023 October 20, 2027
NCT06152575 Recruiting Phase 3 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) February 8, 2024 March 24, 2028
NCT06158841 Recruiting Phase 3 Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma May 9, 2024 January 25, 2028
NCT06169215 Recruiting Phase 2 Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma November 16, 2024 September 30, 2026
NCT06189833 Recruiting Phase 2 Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS November 23, 2023 December 2025
NCT06192979 Recruiting N/A Optimize First-line Treatment for AL Amyloidosis With t (11; 14) January 5, 2024 June 30, 2026
NCT03136146 Recruiting Phase 2 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia August 9, 2017 August 1, 2026
NCT06203145 Recruiting N/A A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM January 2, 2024 November 30, 2025
NCT03390387 Recruiting N/A Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) November 2015 November 2025
NCT06208150 Recruiting Phase 3 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide January 22, 2024 June 30, 2030
NCT06284395 Recruiting Two Schemes Response in Multiple Myeloma November 20, 2023 March 30, 2024
NCT06342466 Recruiting Phase 2 Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis May 6, 2024 December 2026
NCT03590171 Recruiting Phase 2 International Study for Treatment of High Risk Childhood Relapsed ALL 2010 September 1, 2017 December 31, 2027
NCT03641456 Recruiting Phase 2 VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma September 25, 2020 December 30, 2025
NCT03643276 Recruiting Phase 3 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 July 15, 2018 July 14, 2028
NCT03729804 Recruiting Phase 3 Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) May 7, 2019 December 24, 2024
NCT03737136 Recruiting N/A Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR November 1, 2019 October 1, 2025
NCT03759093 Recruiting Phase 2/Phase 3 CURATE.AI Optimized Modulation for Multiple Myeloma September 10, 2023 September 10, 2025
NCT03850366 Recruiting Phase 2 HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib March 8, 2016 January 1, 2026
NCT03993262 Recruiting Phase 2 Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis May 13, 2020 April 30, 2026
NCT04052880 Recruiting Phase 2 Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM October 24, 2019 June 2025
NCT04091126 Recruiting Phase 1 Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma December 18, 2019 June 2, 2025
NCT04240054 Recruiting Phase 2 Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients November 2, 2021 December 1, 2026
NCT04268498 Recruiting Phase 2 A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma February 11, 2020 February 1, 2027
NCT04352205 Recruiting Phase 2 Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure May 7, 2020 April 30, 2024
NCT04414475 Recruiting Phase 2 A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM July 1, 2020 June 30, 2025
NCT04433156 Recruiting Phase 2 VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma April 22, 2020 April 22, 2025
NCT04484623 Recruiting Phase 3 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma October 1, 2020 May 1, 2029
NCT04566328 Recruiting Phase 3 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial February 24, 2021 December 31, 2027
NCT04626791 Recruiting Phase 2 Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma August 3, 2021 August 3, 2028
NCT04754945 Recruiting Phase 1 Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis April 28, 2021 September 21, 2026
NCT04775550 Recruiting Phase 2 DARA RVD For High Risk SMM March 8, 2021 March 8, 2029
NCT04802356 Recruiting Phase 2 Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients April 7, 2021 July 2025
NCT04915248 Recruiting Phase 2 Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. July 11, 2022 June 1, 2024
NCT04923893 Recruiting Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy August 19, 2021 December 13, 2034
NCT04975997 Recruiting Phase 3 Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) June 23, 2022 June 25, 2032
NCT04996160 Recruiting Phase 1 Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) July 9, 2021 December 2025
NCT00772668 Terminated N/A Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL September 25, 2009 February 2011
NCT00871546 Terminated Phase 2 SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) March 2009 December 2010
NCT00441168 Terminated Phase 2 Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma December 2006 January 2008
NCT00920556 Terminated Phase 2 A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma March 30, 2009 November 4, 2010
NCT03117361 Terminated Phase 2 Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide May 8, 2017 July 30, 2018
NCT00923247 Terminated Phase 1/Phase 2 A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) February 19, 2009 December 9, 2016
NCT01536067 Terminated Phase 2 Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia April 2012
NCT00416793 Terminated Phase 2 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer December 2006 December 2009
NCT00983346 Terminated Phase 2 Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients October 2009 September 2014
NCT01537861 Terminated Early Phase 1 Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma June 2012 December 2014
NCT01002248 Terminated Phase 3 Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients December 2009 March 2013
NCT01548573 Terminated Phase 2 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment May 2012 August 2014
NCT00006773 Terminated Phase 1 Bortezomib in Treating Patients With Recurrent Glioma May 2001
NCT01863004 Terminated Phase 1 Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin December 2012 September 15, 2017
NCT03481556 Terminated Phase 1/Phase 2 Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM April 12, 2018 February 2, 2022
NCT03515200 Terminated Phase 1 Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia April 20, 2018 July 29, 2020
NCT04912427 Terminated Phase 1 Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease April 1, 2022 January 26, 2024
NCT00096005 Terminated Phase 1 Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas November 2004
NCT01056601 Terminated Phase 2 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy September 2010 February 2011
NCT00372905 Terminated Phase 1/Phase 2 Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma July 24, 2007 July 8, 2013
NCT00671112 Terminated Phase 1 Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma June 2008
NCT00366106 Terminated Phase 2 Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma July 2006 March 2011
NCT01078441 Terminated Phase 2 Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant September 2010 March 2014
NCT00361621 Terminated Phase 2 Ph II CHOP+Velcade in Mediastinal LBCL July 2006 May 2008
NCT00085410 Terminated Phase 2 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder January 2004 April 2010
NCT01111188 Terminated Phase 1 Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma August 23, 2010 April 12, 2019
NCT01125293 Terminated Phase 1/Phase 2 Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia April 2010 August 2014
NCT01653418 Terminated Phase 2 Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation September 2012 December 2013
NCT00765102 Terminated Phase 2 Trial of Romidepsin and Bortezomib for Multiple Myeloma September 1, 2008 March 1, 2010
NCT01163786 Terminated Phase 2 A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD October 7, 2010 September 9, 2015
NCT00290706 Terminated Phase 1/Phase 2 A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma April 7, 2006 September 5, 2012
NCT00271804 Terminated Phase 1 Study of Velcade and Thalidomide in Patients With Myelodysplasia June 2005 April 2007
NCT01177683 Terminated Phase 1/Phase 2 Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma July 2010 December 2017
NCT00744354 Terminated Phase 1 Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma October 2008 April 2015
NCT00718640 Terminated Phase 2 An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function October 2007 January 2010
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT00265928 Terminated Phase 2 Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT01312818 Terminated Phase 2 Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) June 2011 January 2013
NCT00243035 Terminated Phase 1/Phase 2 Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma August 2005
NCT01315873 Terminated Phase 2 Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma September 2011 September 2015
NCT00066625 Terminated Phase 1 Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer July 2003
NCT01349595 Terminated Phase 2 Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation December 2011 March 2015
NCT01350232 Terminated N/A Treatment of Sickle Cell Anemia With Stem Cell Transplant September 2009 August 2011
NCT00714246 Terminated Phase 1 Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer October 2008 May 2013
NCT02102594 Terminated Phase 2 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) October 2014 August 30, 2019
NCT00148018 Terminated Phase 2 Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma March 2005
NCT00040768 Terminated Phase 2 Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer April 2002
NCT00136591 Terminated Phase 2 A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma September 2005 January 2010
NCT00023881 Terminated Phase 2 Bortezomib in Treating Patients With Chronic Myelogenous Leukemia July 2, 2001 March 2005
NCT02254551 Terminated Phase 2 Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma January 2015 October 2015
NCT02265510 Terminated Phase 1/Phase 2 An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies September 10, 2014 February 27, 2019
NCT01397591 Terminated Phase 2 Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma October 2011 July 2013
NCT00719901 Terminated Phase 1/Phase 2 Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma July 2008 June 2012
NCT00560352 Terminated Phase 1 Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma February 2008 February 2011
NCT00124579 Terminated Phase 2 S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma August 2005 June 2010
NCT02353468 Terminated Phase 2 Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant December 2009 October 2011
NCT02353572 Terminated Phase 1/Phase 2 Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma November 2009 September 2011
NCT02356458 Terminated Phase 1/Phase 2 Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma August 31, 2015 March 30, 2021
NCT00657553 Terminated Phase 3 Preemptive Strike With Bortezomib in Multiple Myeloma Patients February 2008 January 2009
NCT00548717 Terminated Phase 2 Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation October 2007 September 2013
NCT02419755 Terminated Phase 2 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies April 14, 2015 December 31, 2016
NCT00103272 Terminated Phase 1 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer April 2005
NCT00538187 Terminated Phase 1 Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma December 2007
NCT01453088 Terminated Phase 2 Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older June 24, 2010 May 1, 2022
NCT01769443 Terminated Phase 2 Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation June 2013 July 2014
NCT02484261 Terminated Phase 1 Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children May 2015
NCT02489500 Terminated Phase 3 Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib June 2015 April 28, 2017
NCT01465386 Terminated Phase 2 Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission November 2011 March 2, 2015
NCT01470131 Terminated Phase 3 A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma May 2011 February 1, 2017
NCT01954784 Terminated Phase 1 Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma October 7, 2013 January 30, 2017
NCT02518750 Terminated Phase 2 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma November 23, 2016 March 11, 2018
NCT00522392 Terminated Phase 3 Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone September 2007 July 2014
NCT00103103 Terminated Phase 2 Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer March 2005 August 2005
NCT00510887 Terminated Phase 2 Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma January 2007 September 2013
NCT02773550 Terminated Phase 4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma January 2014 July 2018
NCT00464178 Terminated Phase 2 A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma April 2007 February 2009
NCT00793650 Terminated Phase 1/Phase 2 Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study May 2005 September 2011
NCT02877082 Terminated Phase 2 Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients September 2016 July 2017
NCT01902862 Terminated Phase 2 An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma February 2006 August 2007
NCT00810576 Terminated Phase 2 Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma January 2009 April 2010
NCT01728259 Terminated Phase 1 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD March 2013 October 31, 2018
NCT02928029 Terminated Phase 1/Phase 2 Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma February 10, 2017 March 20, 2019
NCT00818649 Terminated Phase 2 Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia January 2009 May 2012
NCT04956302 Terminated Phase 1 Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma September 27, 2021 June 16, 2022
NCT00849251 Terminated Phase 1/Phase 2 Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma November 2008 June 2015
NCT00851552 Terminated Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment January 2009 September 2011
NCT01534143 Terminated Phase 2 High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant February 2012 May 2013
NCT00869323 Terminated Phase 2 Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders March 2009 December 2016
NCT02844322 Unknown status Phase 4 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia May 2016 May 2020
NCT01439750 Unknown status Phase 1 Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) May 2012 August 2020
NCT01328236 Unknown status Phase 2 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia September 2010 September 2015
NCT03443570 Unknown status Phase 3 Rituximab Combining Bortezomib Versus Rituximab in Management of ITP March 1, 2018 March 1, 2021
NCT02955810 Unknown status Phase 1 Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) November 2016 November 2020
NCT04061772 Unknown status Phase 2 A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma August 12, 2019 December 5, 2021
NCT02522572 Unknown status Phase 1/Phase 2 Quantitating the Impact of Plerixafor August 2015 October 2020
NCT03589222 Unknown status Phase 2 SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma July 15, 2018 August 2023
NCT02027220 Unknown status Phase 2 Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma December 2013 December 2015
NCT03844360 Unknown status Phase 4 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease January 31, 2016 December 31, 2021
NCT02976272 Unknown status Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple June 7, 2016 January 31, 2021
NCT03607643 Unknown status Phase 1/Phase 2 A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies January 15, 2019 December 15, 2020
NCT05383547 Unknown status N/A Bortezomib for Treating Glomerular Diseases August 2, 2022 December 31, 2023
NCT02525172 Unknown status Phase 4 Immune Modulation Therapy for Pompe Disease August 2015 July 2020
NCT00508209 Unknown status Phase 2 Bortezomib and High-dose Melphalan at Myeloma Relapse July 2007 September 2010
NCT01449344 Unknown status Phase 3 Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL May 9, 2009 December 2018
NCT04678089 Unknown status Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics May 16, 2019 December 2023
NCT02086942 Unknown status Phase 2 Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. August 2013 August 2017
NCT02362165 Unknown status Phase 3 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma April 2015 May 2018
NCT01965977 Unknown status Phase 2 Bortezomib Maintenance in High Risk DLBCL April 8, 2015 October 30, 2021
NCT00334932 Unknown status Phase 1/Phase 2 Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma February 2006
NCT03700229 Unknown status Phase 2 Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A October 10, 2018 April 15, 2020
NCT02542111 Unknown status Phase 2 A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL May 2015 May 2018
NCT02109861 Unknown status Early Phase 1 Microdose Study of Melphalan, Bortezomib and Dexamethasone January 2014 December 2015
NCT00310037 Unknown status Phase 2 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma June 2006
NCT01842074 Unknown status Phase 4 Desensitization With Bortezomib Before a Living Kidney Donation March 2013 March 2018
NCT03013114 Unknown status Phase 2 A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) January 2017 December 2017
NCT03016988 Unknown status Phase 2 The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma January 2017 December 2020
NCT03103555 Unknown status Phase 2 Treatment of Adult-Onset Immunodeficiency With Bortezomib February 27, 2017 November 1, 2019
NCT00438841 Unknown status Phase 2 Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma August 2006
NCT01255527 Unknown status Phase 1/Phase 2 Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study October 2010 December 2014
NCT05137860 Unknown status Phase 4 Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD December 12, 2021 June 23, 2023
NCT03982771 Unknown status Phase 2 BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) January 1, 2019 January 1, 2023
NCT00431990 Unknown status Phase 1/Phase 2 A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma November 2006 January 2012
NCT01158105 Unknown status Phase 2 Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) June 2010 January 2017
NCT00261612 Unknown status Phase 2 Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma January 2005 January 2007
NCT02797041 Unknown status Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment. August 2015 June 2016
NCT00742404 Unknown status Phase 2 Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma July 2008
NCT00411905 Unknown status Phase 1/Phase 2 Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes June 2006 June 2006
NCT00311337 Unknown status Phase 2 VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) October 2005 October 2010
NCT00389701 Unknown status Phase 2 Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment March 2006
NCT00516100 Unknown status Phase 1/Phase 2 Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC January 2006 August 2012
NCT03335098 Unknown status Phase 2 Study of VTD in Waldenstrom's Macroglobulinemia November 21, 2016 December 2020
NCT02351427 Unknown status Phase 3 Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation February 2015 December 2015
NCT03345303 Unknown status Phase 3 Bortezomib in Intrahepatic Cholangiocellular Carcinoma January 2017 December 2022
NCT01950611 Unknown status Phase 2 Proteasome Inhibition in Acute Promyelocytic Leukemia May 2013 May 2018
NCT04474938 Unknown status Phase 2 Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis May 24, 2021 March 2024
NCT02559154 Unknown status Phase 4 Modified Bortezomib-based Combination Therapy for Multiple Myeloma July 2010 December 2018
NCT01647165 Withdrawn Phase 2 Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance July 11, 2012 June 26, 2015
NCT00504101 Withdrawn Phase 1 Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma June 2007 June 2011
NCT00610792 Withdrawn Phase 2 Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens July 2006
NCT00723658 Withdrawn Phase 2 S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia September 2008
NCT01492881 Withdrawn Phase 2 Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma April 2012 January 2017
NCT04776850 Withdrawn Early Phase 1 Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies December 29, 2020 December 5, 2022
NCT02658396 Withdrawn Phase 1 GO-203-2C + Bortezomib For Relapsed Or Refractory MM January 2022
NCT04392648 Withdrawn Phase 1 A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) June 24, 2020 November 10, 2023
NCT01386398 Withdrawn Phase 3 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
NCT05293509 Withdrawn Phase 2 Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders March 2, 2022 September 18, 2023
NCT03000634 Withdrawn Phase 2 2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy May 2017 May 2023
NCT03130348 Withdrawn Phase 2 Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis March 15, 2018 April 2022
NCT03168100 Withdrawn Phase 2 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma October 1, 2017 January 24, 2019
NCT00411593 Withdrawn Phase 1/Phase 2 Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC) November 2006 May 2007
NCT00995059 Withdrawn Phase 1/Phase 2 Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT05895201 Withdrawn Phase 1/Phase 2 High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD November 2023 December 2025
NCT01680796 Withdrawn Phase 1 Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma February 2013 February 2013
NCT01329289 Withdrawn Phase 2 SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma December 2011 February 2012
NCT02605356 Withdrawn Phase 1/Phase 2 Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma October 2016 July 2021
NCT03591744 Withdrawn Phase 1 Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia October 25, 2018 October 25, 2019
NCT01055301 Withdrawn Phase 2 S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma July 2011 July 2011
NCT03617484 Withdrawn Phase 2 Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma July 2020 July 2030
NCT02082405 Withdrawn Phase 2 Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma April 2015
NCT03701321 Withdrawn Phase 1/Phase 2 Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma January 25, 2019 May 28, 2020
NCT04285268 Withdrawn Phase 2 Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma May 6, 2020 September 30, 2024